Get the Stockscreener App
125.45
0.26%
0.33
After Hours:
125.26
-0.19
-0.15%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $125.45, with a volume of 13.39M.
It is up +0.26% in the last 24 hours and down -0.55% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$125.12
Open:
$125.04
24h Volume:
13.39M
Relative Volume:
2.10
Market Cap:
$218.14B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
15.74
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
-0.01%
1M Performance:
-0.55%
6M Performance:
-5.26%
1Y Performance:
+11.59%
1-Day Range:
$123.76
$126.13
1-Week Range:
$123.76
$129.64
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
125.45 | 217.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
95.61 | 142.48B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.20 | 135.04B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.63 | 126.25B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.66 | 49.21B | 5.88B | 1.34B | 799.60M | 2.3489 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Voya Investment Management LLC Lowers Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Meadowbrook Wealth Management LLC Acquires New Stake in Abbott Laboratories $ABT - MarketBeat
Abbott’s biowearable: One sensor for glucose, ketones - Abbott
Abbott secures FDA and CE Mark approvals for Amplatzer delivery system - Medical Device Network
Abbott wins appeal to restore glucose monitoring patent - Life Sciences Intellectual Property Review
Abbott (ABT): Assessing Valuation After New Regulatory Wins for Its Pediatric Heart Device Innovation - Yahoo Finance
What Abbott Laboratories (ABT)'s New Pediatric Heart Device Clearances Mean For Shareholders - Yahoo Finance
Abbott's Amplatzer Piccolo(TM) Delivery System Receives FDA Clearance - marketscreener.com
Abbott Laboratories Receives FDA Clearance for Amplatzer Piccolo Delivery System - marketscreener.com
Can Abbott Laboratories (ABT) Deliver Resilient Returns in the Long Term? - Insider Monkey
Abbott wins FDA clearance, CE mark for Amplatzer Piccolo delivery system - MassDevice
New device helps doctors close heart holes in the tiniest preemies - Stock Titan
Peak Financial Advisors LLC Takes Position in Abbott Laboratories $ABT - MarketBeat
2 Dividend Stocks to Buy for 2026 and Beyond - Finviz
Abbott Laboratories $ABT Shares Purchased by Czech National Bank - MarketBeat
Chesley Taft & Associates LLC Sells 9,502 Shares of Abbott Laboratories $ABT - MarketBeat
Is Abbott Laboratories stock a smart buy before Fed meetingTrend Reversal & Weekly High Return Stock Opportunities - Улправда
RBC Capital Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $147 - 富途牛牛
Abbott Laboratories (NYSE:ABT) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Is Abbott Laboratories Still Attractively Priced After Recent Medical Device Momentum In 2025? - simplywall.st
Chris Blumas' Top Picks: Constellation Software, Brookfield Infrastructure & Abbott Labs - BNN Bloomberg
Transcatheter Heart Valve Replacement Market Size to Reach USD 19.98 Billion by 2033, Growing at a CAGR of 15.32% – SNS Insider - GlobeNewswire Inc.
Union Bancaire Privee UBP SA Sells 20,132 Shares of Abbott Laboratories $ABT - MarketBeat
Is Trending Stock Abbott Laboratories (ABT) a Buy Now? - Yahoo Finance
Thurston Springer Miller Herd & Titak Inc. Has $430,000 Stock Position in Abbott Laboratories $ABT - MarketBeat
Nilsine Partners LLC Cuts Stake in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (NYSE:ABT) Shareholders Will Want The ROCE Trajectory To Continue - Yahoo Finance
Abbott Labs Slammed with Unpaid Wages Lawsuit - LawyersandSettlements.com
1 Safe-and-Steady Stock to Consider Right Now and 2 We Turn Down - FinancialContent
Abbott Seeks Federal Protection From Similac NEC Lawsuits - AboutLawsuits.com
TruWealth Advisors LLC Sells 109,352 Shares of Abbott Laboratories $ABT - MarketBeat
Insight Wealth Strategies LLC Invests $4.91 Million in Abbott Laboratories $ABT - MarketBeat
Osaic Holdings Inc. Raises Stock Position in Abbott Laboratories $ABT - MarketBeat
Thrivent Financial for Lutherans Sells 60,906 Shares of Abbott Laboratories $ABT - MarketBeat
Capital Asset Advisory Services LLC Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Home Diagnostics Market Is Going to Boom |• Abbott • Roche Diagnostics - openPR.com
Kidney Function Tests Market Is Going to Boom |• Abbott • Siemens - openPR.com
Reinventing the lab coat - Abbott
Why the Market Dipped But Abbott (ABT) Gained Today - Yahoo Finance
Gastrointestinal Diagnostics (GI) Market to Reach $5.8 Billion by 2030 - GlobeNewswire Inc.
Abbott Gains From Lingo CGM's Expansion on Android Platform - Nasdaq
Abbott Laboratories declares $0.063 dividend - MSN
Rep. Julie Johnson Sells Abbott Laboratories (NYSE:ABT) Stock - MarketBeat
Texas Permanent School Fund Corp Sells 65,976 Shares of Abbott Laboratories $ABT - MarketBeat
Stance Capital LLC Makes New $1.30 Million Investment in Abbott Laboratories $ABT - MarketBeat
Prostate Cancer Diagnostics Market Is Going to Boom |• Abbott • Siemens - openPR.com
Corient Private Wealth LLC Increases Holdings in Abbott Laboratories $ABT - MarketBeat
Caldwell Trust Co Takes Position in Abbott Laboratories $ABT - MarketBeat
17,830 Shares in Abbott Laboratories $ABT Bought by B. Riley Wealth Advisors Inc. - MarketBeat
Abbott Laboratories Strengthens Shareholder Returns Amid Strategic Acquisition - AD HOC NEWS
Abbott Laboratories (ABT) Stock: What to Know Before the U.S. Market Opens on Dec. 15, 2025 - ts2.tech
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):